Takeda Pharmaceutical (TAK) Capital Expenditures Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | -5.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22% |
| Mar 31, 2026 | 1.64% |
| Dec 31, 2025 | -4.53% |
| Sep 30, 2025 | -8.65% |
| Jun 30, 2025 | -0.55% |
| Mar 31, 2025 | 8.41% |
| Dec 31, 2024 | -7.59% |
| Sep 30, 2024 | -5.88% |
| Jun 30, 2024 | -10.62% |
| Mar 31, 2024 | 5.51% |
| Dec 31, 2023 | -10.66% |
| Sep 30, 2023 | -0.59% |
| Jun 30, 2023 | -15.95% |
| Mar 31, 2023 | -2.33% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | -6.25% |
| Mar 31, 2022 | 15.99% |
| Dec 31, 2021 | -27.14% |
| Sep 30, 2021 | -20.70% |
| Jun 30, 2021 | -14.87% |